This perspective is a formal request to the American College of Cardiology and American Heart Association (ACC/AHA) to perform a value analysis on andexanet (Andexxa) similar to what was completed for the PCSK9 inhibitors in the 2018 ACC/AHA Blood Cholesterol guidelines. Based on the safety and efficacy concerns of andexanet alfa, a value statement in and or as an addendum to society guidelines is vital considering the high cost of therapy. In this era of ever-increasing health care costs, every clinician, health system, national society, insurer, and pharmaceutical company should work to be good stewards of our society’s resources.
GundySMStoneNJBaileyAL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guidelines on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285-e350. doi:10.1016/j.jacc.2018.11.003
2.
ConnollySMillingTEikelboomJ, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326-1335. doi:10.1056/NEJMoa1814051
3.
BaughCWLevineMCornuttD, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel [published online November 13, 2019]. Ann Emerg Med. doi:10.1016/j.annemergmed.2019.09.001
4.
CukerABurnettATrillerD, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. Am J Hematol. 2019;94:697-709. doi:10.1002/ajh.25475
5.
MajeedAAgrenAHolmstromM, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017;120:1706-1712. doi:10.1182/blood-2017-05-782060
6.
SchulmanSGrossPLRitchieB, et al. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemost. 2018;118:842-851. doi:10.1055/s-0038-1636541
7.
SmithMDeloneyLCarterCWeantKAErikssonEA.Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis. 2019;48:250-255. doi:10.1007/s11239-019-01846-5
CulbrethSRimsansJSylvesterKPallinDJConnorsJM.Andexanet alfa—the first 150 days. Am J Hematol. 2018;94:E21-E24. doi:10.1002/ajh.25326
10.
PollackCVJrReillyPAEikelboomJ, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511-520. doi:10.1056/NEJMoa15020000
11.
DagerWERobertsAJNishijimaDK.Effect of low and moderate dose FEIBA to reverse major bleeding in patients on oral anticoagulants. Thromb Res. 2019;173:71-76. doi:10.1016/j.thromres.2018.11.009
12.
SarodeRMillingTJJrRefaaiMA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-1243. doi:10.1161/circulationaha.113.002283
13.
GoldsteinJNRefaaiMAMillingTJJr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomized trial. Lancet. 2015;385:2077-2087. doi:10.1016/S0140-6773(14)61685-8
14.
RuppTZuckermanD.Quality of life, overall survival, and cost of cancer drugs approved based on surrogate endpoints. JAMA Intern Med. 2017;177:276-277. doi:10.1001/jamainternmed.2016.7761
15.
ParikhNDSingalAGHuttonDW.Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Cancer. 2017;123:3725-3731. doi:10.1002/cncr.30863
